Fisher & Paykel Healthcare Corporation Ltd (ASX:FPH) is expecting its net profit after tax to trend higher during the 2025 fiscal year, based on the introduction of new products and continuing changes to clinical practice.
The company – whose products focus on acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea – said its net profit after tax (NPAT) is set to be between $320 million to $370 million during FY25, a rise from the figure of between $310 million to $360 million which was indicated by full year guidance provided in May.
Operating revenue was expected to remain on-target for the previous guidance of around $1.9 billion to $2.0 billion.
Managing Director and CEO Lewis Gradon said current activities throughout the business explained the predicted profit growth.
“The year to date has begun strongly across all products and regions,” he said.
“In the Hospital product group, contributions include ongoing change in clinical practice, and a good response to new product introductions.
“In addition, early indications are that the year to date includes a relatively high hospital census during the period in both the Northern and Southern Hemispheres as Northern Hemisphere seasonal hospitalisations persisted into the beginning of this current financial year and hospitals have returned to more normalised staffing and capacity.
“It is also pleasing to see the progress we are making with our gross margin improvement initiatives as we return to our usual practice of working on efficiency and continuous improvement activities.”
Looking specifically at the first half of FY2025 – which ends on 30 September, 2024 – FPH said revenue would come in between $940 million to $950 million, with and NPAT being in the range of approximately $150 million to $160 million.
This would also represent growth – the company added – of around 18% growth in reported
operating revenue and 44% growth in NPAT, compared to the first half of the 2024 financial year.
FPH has been trading at $29.34